Skip to content

Clinical trials

Lymphoma, T-Cell, Cutaneous trials with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lymphoma, T-Cell, Cutaneous Status: Unknown status Clear all

36 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20021
20051
20072
20084
20092
20102
20142
20152
20162
20171
20181
20194
20211
20223
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status36

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Jonsson Comprehensive Cancer Center3
Assistance Publique - Hôpitaux de Paris2
Herbert Irving Comprehensive Cancer Center2
Peking Union Medical College Hospital2
Auxilio Mutuo Cancer Center1
Cancer Research UK1
Central Hospital, Nancy, France1
Clatterbridge Centre for Oncology1
Far Eastern Memorial Hospital1
Florida Academic Dermatology Centers1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lymphoma, T-Cell, Cutaneous36
Mycosis Fungoides15
Lymphoma14
Lymphoma, Large B-Cell, Diffuse14
Lymphoma, Non-Hodgkin14
Hodgkin Disease13
Leukemia, Lymphocytic, Chronic, B-Cell13
Lymphoma, B-Cell, Marginal Zone13
Lymphoma, Follicular13
Precursor Cell Lymphoblastic Leukemia-Lymphoma13

Trials

Showing 76 to 36 of 36. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.